These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 17618400)

  • 1. Clarithromycin induced torsade de pointes.
    Hensey C; Keane D
    Ir J Med Sci; 2008 Mar; 177(1):67-8. PubMed ID: 17618400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clarithromycin-Induced Torsades de Pointes.
    Chang NL; Shah P; Bikkina M; Shamoon F
    Am J Ther; 2016; 23(3):e955-6. PubMed ID: 25057773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Torsades de pointes due to drug interaction between disopyramide and clarithromycin.
    Choudhury L; Grais IM; Passman RS
    Heart Dis; 1999; 1(4):206-7. PubMed ID: 11720625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azithromycin-induced torsade de pointes.
    Huang BH; Wu CH; Hsia CP; Yin Chen C
    Pacing Clin Electrophysiol; 2007 Dec; 30(12):1579-82. PubMed ID: 18070319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Torsade de pointes induced by cisapride/clarithromycin interaction.
    Piquette RK
    Ann Pharmacother; 1999 Jan; 33(1):22-6. PubMed ID: 9972380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QT prolongation and Torsades de Pointes associated with clarithromycin.
    Lee KL; Jim MH; Tang SC; Tai YT
    Am J Med; 1998 Apr; 104(4):395-6. PubMed ID: 9576415
    [No Abstract]   [Full Text] [Related]  

  • 8. Moxifloxacin and torsade de pointes.
    Dale KM; Lertsburapa K; Kluger J; White CM
    Ann Pharmacother; 2007 Feb; 41(2):336-40. PubMed ID: 17284508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors.
    Kezerashvili A; Khattak H; Barsky A; Nazari R; Fisher JD
    J Interv Card Electrophysiol; 2007 Apr; 18(3):243-6. PubMed ID: 17546486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Torsades de pointes following clarithromycin treatment.
    Gysel M; Vieweg WV; Hasnain M; Hancox JC; Kunanithy V; Baranchuk A
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1485-93. PubMed ID: 24147515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microvolt T-wave alternans monitoring in a patient with levofloxacin-induced Torsade de Pointes.
    Sahashi Y; Takasugi N; Naruse G; Kubota T; Nishigaki K; Minatoguchi S
    J Electrocardiol; 2018; 51(1):108-110. PubMed ID: 29126547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QT interval prolongation, torsade de pointes and renal disease.
    Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
    Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Iatrogenic torsade de pointes induced by thioridazine].
    Paoloni P; Ciliberti D; Blasi N; Capone P
    Minerva Cardioangiol; 1992 Jun; 40(6):245-9. PubMed ID: 1407620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyzine-induced Torsade de Pointes in a Patient with Complete Atrioventricular Block.
    Koshino K; Endo A; Watanabe N; Okazaki K; Tanabe K
    Intern Med; 2021 Oct; 60(20):3257-3260. PubMed ID: 33896871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time- and rate-dependent alterations of the QT interval precede the onset of torsade de pointes in patients with acquired QT prolongation.
    Gilmour RF; Riccio ML; Locati EH; Maison-Blanche P; Coumel P; Schwartz PJ
    J Am Coll Cardiol; 1997 Jul; 30(1):209-17. PubMed ID: 9207644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced torsade de pointes. Incidence, management and prevention.
    Faber TS; Zehender M; Just H
    Drug Saf; 1994 Dec; 11(6):463-76. PubMed ID: 7727055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of erythromycin-induced malignant tachyarrhythmia--torsade de pointes. A case report.
    Katapadi K; Kostandy G; Katapadi M; Hussain KM; Schifter D
    Angiology; 1997 Sep; 48(9):821-6. PubMed ID: 9313632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.
    De Ponti F; Poluzzi E; Cavalli A; Recanatini M; Montanaro N
    Drug Saf; 2002; 25(4):263-86. PubMed ID: 11994029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
    Skanes AC; Morton BC; Green MS; Tang AS
    Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.